Relay Therapeutics Reports Significant Clinical Findings
Relay Therapeutics, Inc. (NASDAQ: RLAY) has shared exciting developments regarding its cancer treatment candidate, zovegalisib (RLY-2608). The company recently presented interim clinical data, which demonstrated a promising activity profile in a specific subset of breast cancer patients.
Understanding the Patient Population
The data, which emerged from a subset analysis, focused on individuals with PI3K? mutations and HR+/HER2- metastatic breast cancer. Interestingly, analysis revealed that patient outcomes did not significantly vary based on prior treatment with fulvestrant or other SERD medications.
Overview of Clinical Findings
During this examination, Relay Therapeutics reported that as of the latest data cut-off on October 15, 2025, there were 118 patients enrolled in the zovegalisib plus fulvestrant arm of the ReDiscover study. The results indicated a median progression-free survival (PFS) of 10.3 months across all participants in the study, showcasing that zovegalisib stands to have a substantial impact.
Efficacy Across Various Subgroups
In-depth evaluation revealed that among 31 patients with measurable disease, the objective response rate (ORR) was 39%. Moreover, for patients treated in the second-line setting, median PFS extended to an impressive 11.4 months with an ORR soaring to 47%. It appears that efficacy remained robust regardless of pre-existing conditions such as prior SERD use or the presence of ESR1 mutations.
Next Steps for Zovegalisib
Looking ahead, Relay Therapeutics is poised for continued clinical exploration with zovegalisib. Plans include advancing the Phase 3 ReDiscover-2 trial, aimed at further studying the combined approach of zovegalisib and fulvestrant specifically among patients presenting with PI3K? mutations. Additionally, researchers are advancing dose escalation in the Phase 1/2 ReDiscover trial to identify optimal combinations for future use.
Overview of Relay Therapeutics' Program
Zovegalisib represents a cornerstone in Relay Therapeutics’ initiative to develop selective inhibitors targeting PI3K?, which has been identified as a frequent mutation in many types of cancer, making this research critical. If zovegalisib receives the necessary approvals, it could potentially serve nearly 500,000 patients in need of tailored cancer treatments within the United States.
Market Reception and Analyst Insights
An analyst recommendation from Wells Fargo recently upgraded Relay Therapeutics from Equal-Weight to Overweight and raised its price forecast from $6 to $13 in light of these encouraging findings. Following this news, Relay Therapeutics shares experienced gains, with a reported rise of 3.21%, trading at $8.03 during the report publication period.
Frequently Asked Questions
What is Relay Therapeutics known for?
Relay Therapeutics focuses on developing precision treatments for various types of cancer, particularly through its innovative drug zovegalisib.
What type of cancer does zovegalisib target?
Zovegalisib primarily targets breast cancer characterized by PI3K? mutations, specifically HR+/HER2- metastatic breast cancer.
What were the main findings of the latest clinical trial?
The trial findings showed a robust activity of zovegalisib in treating breast cancer patients with specific genetic mutations, demonstrating median PFS and response rates that are promising.
What are the future plans for zovegalisib?
Future plans include further clinical trials with zovegalisib, focusing on its efficacy and safety, along with its potential use in combination with other drugs.
How did the market respond to Relay Therapeutics' recent announcement?
Following the announcement, Relay Therapeutics' stock saw a notable increase as analysts responded positively to the promising trial results.
